Charles River Laboratories Introduces PTS-Micro™ System for Rapid Microbial Burden Testing

WILMINGTON, Mass.—October 20, 2014 – Charles River Laboratories International, Inc. (NYSE: CRL) today introduced the PTS-Micro™ system, a new technology platform designed for rapid microbial burden testing. The PTS-Micro is the latest product in the company's expanding portfolio for Microbiology Quality Control that includes the Endosafe® FDA-licensed LAL cartridge technology for endotoxin testing and the Accugenix® Microbial Identification solutions.

The PTS-Micro is a compact instrument that uses solid-phase fluorescence cytometry and modular components to efficiently and rapidly detect for viable microorganisms in multiple samples simultaneously. Whereas current bioburden platforms are classified either as growth-based or direct, the PTS-Micro can easily interchange between these methods to meet specific sensitivity, sample property and time to result requirements, offering unequalled method flexibility and ease of use.

PTS-Micro now positions Charles River with the unique combination of solutions for bioburden testing, endotoxin detection and microbial identifications for the Micro QC lab.

"The PTS-Micro system provides customers who have critical bioburden samples a platform to obtain results sooner and therefore, make go-no-go decisions earlier," said Foster Jordan, Corporate Senior Vice President, Endotoxin and Microbial Detection, Charles River Laboratories. "Its introduction further underscores our commitment in providing rapid, accurate and reliable results for our clients in the biopharmaceutical, medical device and other regulated industries."

The system will be available for demonstrations and evaluations starting fourth quarter 2014.

For more information on this technology, visit or contact [email protected].

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Charles River's dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about Charles River's unique portfolio and breadth of services, visit

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.